Brazil's Vaccine Regulation Update
Brazil's National Health Surveillance Agency (ANVISA) has approved new regulations aimed at updating COVID-19 vaccines to enhance their effectiveness against emerging variants of the virus.
These regulations align with international standards and incorporate recommendations from organizations such as the International Coalition of Medicines Regulatory Authorities (ICMRA) and the World Health Organization (WHO), ensuring that Brazil's vaccine protocols meet global best practices.
The primary objective of these updates is to improve the immune response elicited by vaccines, thereby providing robust and long-lasting protection against new variants of the SARS-CoV-2 virus. The regulations outline specific strains to be included in vaccines and establish clear guidelines for their updates.
The new rules were approved during the 17th Ordinary Public Meeting of ANVISA’s Collegiate Board of Directors on September 18, 2024. The WHO will continue to monitor the evolution of SARS-CoV-2 and provide ongoing recommendations for vaccine composition.
Regulatory Impact
- Top Priority: Yes
- Type of Certificate: No
- Spectrum Bands: No
- Import Changes HS Codes: No
- Standard Changes: Yes
- Product Changes: No
- Label Changes: No
Regulatory Impact
| Impact Type | Status |
|---|---|
| Top Priority | |
| Type Certificate | |
| Spectrum Bands | |
| Import Changes (HS Codes) | |
| Standard Changes | |
| Product Changes | |
| Label Changes |